MK 2866 (Ostarine) by Dragon Pharma

MK-2866 Ostarine — Enobosarm by Dragon Pharma

MK-2866 (Ostarine, Enobosarm) is Dragon Pharma's formulation of the most extensively human-trialled SARM at 25mg per tablet. Developed by GTx Incorporated under the clinical name Enobosarm, Ostarine is the only SARM to have completed Phase III clinical trials in humans — providing a clinical data set that no other SARM in the range can match. It binds androgen receptors with tissue selectivity favouring muscle and bone over prostate and sebaceous glands, producing anabolic effects with reduced androgenic side effects compared to testosterone.

Also searched as: Ostarine 25mg, MK 2866, Enobosarm, MK-2866 SARM Dragon Pharma.

What Ostarine Is — SARM Classification Explained

SARMs (Selective Androgen Receptor Modulators) are non-steroidal compounds that bind androgen receptors with tissue-selective activity:

• Unlike anabolic steroids (which are steroidal molecules activating androgen receptors throughout the body), SARMs are small organic molecules that bind the AR with a different conformational profile — recruiting different co-activators in different tissue types
• In muscle and bone tissue, the AR-SARM complex recruits co-activators that drive anabolic gene expression (protein synthesis, myogenesis, osteogenesis)
• In androgenic tissues (prostate, sebaceous glands, hair follicles), the AR-SARM complex recruits fewer or different co-activators — producing reduced androgenic stimulation at equivalent anabolic effect
• Ostarine's approximate selectivity ratio is 10:1 (anabolic:androgenic) — meaning 10 units of anabolic muscle effect for every 1 unit of androgenic effect, compared to testosterone's approximately 1:1 ratio

The Phase III Clinical Trial Data — What Enobosarm's Trials Actually Found

Ostarine's Phase III history provides uniquely specific human data — and some honest findings that competitor content glosses over:

• GTx conducted two Phase III trials (POWER1 and POWER2, 2013) in cancer patients at risk of cachexia — testing Enobosarm 3mg/day for 112 days. Primary endpoint was stair-climb power and lean body mass
• Results were mixed: lean body mass was preserved/increased versus placebo, but the primary endpoint statistical significance was inconsistent between trials — leading to FDA rejection of the NDA and GTx deprioritising development
• Critically for performance users: at 3mg/day in cancer patients, meaningful lean mass preservation was achieved — confirming anabolic efficacy in humans. Performance users typically use 10-25mg/day, substantially above the clinical trial dose
• The trials also confirmed: dose-dependent HDL reduction (cholesterol effects exist even with SARMs), mild HPG axis suppression at all clinical doses tested, and no significant hepatotoxicity at these doses

The Suppression Reality — Why Ostarine Requires PCT

This is the most commonly misrepresented aspect of Ostarine in competitor content:

• The "SARMs don't suppress testosterone" claim is incorrect. Ostarine, like all AR agonists, produces HPG axis suppression through negative feedback — the same mechanism as AAS, via AR-mediated inhibition of LH and FSH secretion
• The suppression from Ostarine is milder than equivalent anabolic doses of testosterone — typically 20-40% reduction in LH and FSH at 25mg/day for 8 weeks, compared to near-complete suppression from a testosterone cycle
• However, 20-40% LH/FSH suppression still results in meaningful testosterone reduction — typically falling to the lower end of normal range or below during Ostarine use
• Post-cycle recovery is faster than from an AAS cycle — natural testosterone typically recovers within 4-6 weeks post-Ostarine without PCT, but PCT significantly accelerates this and is advisable for longer cycles (8+ weeks) or higher doses (25mg+)

Ostarine vs Other SARMs — The Range Comparison

Effects and Benefits

• Lean muscle mass preservation and modest gains — most documented in clinical trials for this purpose
• Bone density support — androgen receptor activation in bone tissue, relevant for injury recovery
• Joint and connective tissue support — commonly reported anecdotally; consistent with AR-driven collagen synthesis in connective tissue
• Mild fat loss support — AR activation in adipose tissue has lipolytic effects
• No aromatisation — no estrogenic side effects from Ostarine itself
• Minimal androgenic side effects at clinical and performance doses

Dosage and Administration

Ostarine's ~24-hour half-life allows once-daily dosing — morning or evening both work given the flat blood level profile. The 25mg Dragon Pharma tablet is appropriate for the standard performance dose; users starting conservatively can split the tablet. Cycle length above 8 weeks at 25mg consistently produces meaningful suppression that warrants PCT.

PCT for Ostarine

Ostarine PCT is lighter than post-AAS PCT — reflecting the milder degree of suppression:

• Nolvadex at 20mg/day for 4 weeks, or 40mg/day for 2 weeks then 20mg/day for 2 weeks
• Alternatively Clomid at 25mg/day for 4 weeks — lower doses than post-AAS reflect the milder suppression
• Begin PCT 24-48 hours after the last Ostarine tablet — the 24-hour half-life means blood levels decline quickly post-cessation, unlike long-ester AAS that require weeks before PCT

Ostarine in a Protocol

• During AAS PCT — Ostarine at 12.5-25mg/day is used by some during PCT to maintain muscle mass while testosterone recovers. This is a debated practice: the additional mild AR stimulation may help preserve gains, but adds AR agonism to a phase where the goal is HPG recovery
• MK-677 alongside Ostarine — oral GH secretagogue combined with oral SARM for a fully injection-free anabolic protocol
• GW-501516 (Cardarine) alongside Ostarine — adding PPARδ-driven endurance and fat oxidation to Ostarine's AR anabolic effects

Storage and Handling

Store MK-2866 at room temperature, away from direct sunlight and moisture. Keep the original packaging sealed until use to maintain tablet potency.